Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Korlym

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 911Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Judge Pauses Louisiana's Challenge to FDA Abortion Drug Rule
    Judge Pauses Louisiana's Challenge to FDA Abortion Drug Rule

    10 Apr 2026

    // REUTERS

    https://www.reuters.com/legal/government/us-judge-pauses-louisianas-challenge-fda-abortion-drug-rule-2026-04-07/

    REUTERS
    10 Apr 2026
    Share Share
    FDA Plans Another Safety Study Of Abortion Drug After Court Order
    FDA Plans Another Safety Study Of Abortion Drug After Court Order

    09 Apr 2026

    // ENDPOINTS

    https://endpoints.news/fda-plans-another-safety-study-of-abortion-drug-after-court-order/

    ENDPOINTS
    09 Apr 2026
    Share Share
    US FDA Has Delayed Abortion Pill Safety Study
    US FDA Has Delayed Abortion Pill Safety Study

    10 Dec 2025

    // BLOOMBERG

    https://news.bloomberglaw.com/health-law-and-business/fda-slow-walking-a-long-awaited-abortion-pill-safety-study

    BLOOMBERG
    10 Dec 2025
    Share Share
    SameDayAbortionPills Notes Occasional Pharmacy Refusals
    SameDayAbortionPills Notes Occasional Pharmacy Refusals

    17 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251017030596/en/SameDayAbortionPills-Notes-That-While-Major-Pharmacies-Strive-to-Dispense-Abortion-Pills-Consistently-Occasional-Refusals-Still-Occur-Due-to-Individual-Human-Factors

    BUSINESSWIRE
    17 Oct 2025
    Share Share
    Optime Care Terminates Distributor Agreement for Korlym
    Optime Care Terminates Distributor Agreement for Korlym

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164304/0/en/Optime-Care-Terminates-Distributor-Agreement-for-Korlym-mifepristone.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    FDA Approves Another Generic Version of Abortion Pill
    FDA Approves Another Generic Version of Abortion Pill

    03 Oct 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-generic-version-abortion-drug-2025-10-02/

    REUTERS
    03 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.